Neuroprotective Properties: Dihexa may offer neuroprotective effects, potentially safeguarding the brain from degeneration and damage, which is important in maintaining cognitive abilities over time
Structurally, semaglutide is an acylated peptide analogue of native GLP-1
Both were removed from the FDA Category 2 list in April 2026, and on July 23 to 24, 2026 the advisory committee voted to recommend them for the 503A list
Semaglutide typically produces more dramatic total weight loss but includes muscle and water loss along with fat, whereas AOD-9604 more selectively targets fat tissue
We also address current barriers to implementation and evidence-based use, ongoing clinical trials, and future directions, including combination therapies that may enhance efficacy and patient outcomes
Application number: 209637Orig1s000